Oncology Corporate Profile
Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura Oncology's diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology's approach to drug development is focused on rapidly translating novel science into life-saving medicines.
Website: http://www.kuraoncology.com/
Brand / Product | Class | Area of Study | Phase | Partnership |
---|---|---|---|---|
tipifarnib | farnesyl transferase inhibitors | Chronic Myelomonocytic Leukemia | II | |
tipifarnib | farnesyl transferase inhibitors | Myelodysplastic Syndrome (MDS) | II | |
tipifarnib | farnesyl transferase inhibitors | T-cell Lymphoma | II | |
tipifarnib | farnesyl transferase inhibitors | Various cancer types | II | |
KO-947 | ERK inhibitor | Various cancer types | I | |
KO-539 | menin MLL inhibitor | Leukemia | Preclinical |
View additional information on product candidates here »